November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

New National Guidance Issued for Severe Withdrawal Linked to Medetomidine

🏥 Public Health 2 min read 👁 0

The American Society of Addiction Medicine has released its first national considerations for identifying and treating withdrawal from medetomidine, a potent sedative increasingly found in illicit drug supplies.

New National Guidance Issued for Severe Withdrawal Linked to Medetomidine🏥Public Health

Photo: statnews.com

Key points

  • The American Society of Addiction Medicine released initial clinical considerations for medetomidine withdrawal.
  • Medetomidine is a potent sedative frequently mixed into illicit opioid supplies across multiple states.
  • Severe withdrawal can cause extreme blood pressure spikes and heart rate changes, often requiring intensive care.

The American Society of Addiction Medicine has published its first clinical considerations for recognizing and managing withdrawal from medetomidine, a powerful sedative that has surfaced in illicit drug markets across the United States. While clinicians initially detected the substance in the Philadelphia drug supply during early 2024, health providers across at least 18 states had identified it by late 2025. Experts note that medetomidine is nearly always combined with illicit opioids, complicating standard overdose responses because patients may remain heavily sedated even after receiving naloxone.

Unlike traditional opioid withdrawal, coming off medetomidine triggers distinct physiological complications, including severe nausea and vomiting without diarrhea, followed rapidly by dangerously high blood pressure and elevated heart rates if left unmanaged. The newly released document outlines treatment approaches, suggesting the use of medications such as clonidine or intravenous dexmedetomidine to stabilize patients. Because medetomidine is significantly more potent than xylazine, another common illicit drug adulterant, withdrawal symptoms can be severe enough to require intensive care unit admission.

Physicians emphasize that medetomidine withdrawal symptoms can mimic other medical emergencies like sepsis, making local drug supply awareness essential for healthcare providers. Because these recommendations rely on clinical observations rather than large-scale randomized trials, experts frame them as preliminary considerations rather than definitive guidelines. Patients and families navigating substance use concerns are encouraged to consult qualified healthcare professionals for medical advice and tailored treatment options.

What to know: Medetomidine, a potent veterinary sedative, has been increasingly detected as an adulterant in the illicit opioid supply across multiple states, leading to severe withdrawal symptoms that may require intensive hospital care.

Source statnews.com — statnews.com/2026/11/13/medetomidine-withdrawal-asam-new-treatment-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.